ReviewVaccine2023
Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
Review in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Avian Influenza Virus Infection and Outcomes during Pregnancy.Emerging infectious diseases · 2025Pooled it
- Characterizing persistent Post-COVID-19 vaccination symptoms using MedDRA system organ class and preferred term classifications.Scientific reports · 2026Article
- Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Observational
- The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.Pharmaceutics · 2024Review
- Article
- Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines.Vaccines · 2024Review
- [Experience of setting up a state pharmacovigilance committee during the COVID-19 pandemicExperiencia de la puesta en marcha de un comité estatal de farmacovigilancia durante la pandemia de COVID-19].Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study.Frontiers in public health · 2024Article
- Case reports as early safety signals: learning from the COVID-19 vaccination campaign.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the roll out of vaccines during a pandemic, questions regarding vaccine safety often arise. This was surely true during the SARS-CoV-2 pandemic. Different tools and capabilities exist during the pre-authorization phase and post introduction each with its strengths and limitations. Here we review the various tools and their strengths and limitations and discuss what functioned well in high income settings and the limitations that unequal vaccine safety pharmacovigilance capacity imposed upon middle and low income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.